Skip to content
OpenCapital
Get started

ImmunityBio, Inc. IBRX IPR&D, gross

Other financials

Income statement

See full
Revenue$44.2M+168%
Gross profit$44.0M+167%
Operating income-$69.8M-8.3%
Net income-$632.8M-388%
EPS (diluted)-$0.62-313%

Balance sheet

See full
Cash & equivalents$205.2M+238%
Total debt$445.4M+32.2%
Total equity-$870.0M-47.1%
Total assets$646.6M+113%

Cash flow

See full
Operating cash flow-$75.4M+12.3%
CapEx$1.8M+58.4%
Free cash flow-$77.1M+11.4%

Valuation

See full
Market cap$7.71B+208%
Enterprise value$7.95B+187%
P/S54.7×-25.4×

Profitability

See full
Gross margin99.3%-0.5pp
Operating margin-185.4%-83.3pp
Net margin-606.2%-212pp
FCF margin-212%-95.8pp

Returns & leverage

See full
Return on equity-119.3%—
Debt / equity0.1×—
Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept ibrx:IndefiniteLivedIntangibleAssetsGrossExcludingGoodwill.

The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s ipr&d, gross.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ImmunityBio, Inc.'s ipr&d, gross?
ImmunityBio, Inc. (IBRX) reported ipr&d, gross of $62K in Q1 2026.
How has ImmunityBio, Inc.'s ipr&d, gross changed year-over-year?
ImmunityBio, Inc.'s ipr&d, gross decreased by 87.8% year-over-year, from $510K to $62K.
What is the long-term trend for ImmunityBio, Inc.'s ipr&d, gross?
Over 2 years (2023 to 2025), ImmunityBio, Inc.'s ipr&d, gross has grown at a -80.8% compound annual growth rate (CAGR), from $1.41M to $52K.